Patents Assigned to Pfizer
  • Drug loaded polymeric nanoparticles and methods of making and using same
    Patent number: 9579386
    Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: February 28, 2017
    Assignee: Pfizer Inc.
    Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
  • Cycloalkyl-Linked Diheterocycle Derivatives
    Publication number: 20170050958
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 23, 2017
    Applicant: PFIZER INC.
    Inventors: Aaron Craig BURNS, Michael Raymond COLLINS, Samantha Elizabeth GREASLEY, Robert Louis Hoffman, Peter Qinhua HUANG, Robert Steven Kania, Pei-Pei KUNG, Maria Angelica LINTON, Lakshmi Sourirajan NARASIMHAN, Paul Francis RICHARDSON, Daniel Tyler RICHTER, Graham SMITH
  • ANTIBODY-DRUG CONJUGATES WITH HIGH DRUG LOADING
    Publication number: 20170043033
    Abstract: The present invention provides transglutaminase-mediated antibody-drug conjugates with high anti-body-drug ratio (DAR) comprising 1) glutamine-containing tags, endogenous glutamines, and/or endogenous glutamines made reactive by antibody engineering or an engineered transglutaminase (e.g., with altered substrate specifity); and 2) amine donor agents comprising amine donor units, linkers, and agent moieties, wherein the DAR is at least about 5. The invention also provides methods of making and methods of using such higher drug loaded antibody-drug conjugates.
    Type: Application
    Filed: April 21, 2015
    Publication date: February 16, 2017
    Applicants: RINAT NEUROSCIENCE CORP., PFIZER INC.
    Inventors: Pavel STROP, Katherine Anne DELARIA, Magdalena DORYWALSKA, Davide Luciano FOLETTI, Russell George DUSHIN, David Louis SHELTON, Arvind RAJPAL
  • HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
    Publication number: 20170044174
    Abstract: The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
    Type: Application
    Filed: April 14, 2015
    Publication date: February 16, 2017
    Applicant: PFIZER INC.
    Inventors: DAVID LAWRENCE FIRMAN GRAY, LEI ZHANG, MICHAEL AARON BRODNEY, JENNIFER ELIZABETH DAVOREN, IVAN VIKTOROVICH EFREMOV, MICHAEL ERIC GREEN, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS
  • HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
    Publication number: 20170037053
    Abstract: The present invention provides, in part, compounds of Formula (I) and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
    Type: Application
    Filed: April 13, 2015
    Publication date: February 9, 2017
    Applicant: PFIZER INC.
    Inventors: DAVID LAWRENCE FIRMAN GRAY, LEI ZHANG, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, CHEWAH LEE, SCOT RICHARD MENTE, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, CHAKRAPANI SUBRAMANYAM
  • HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
    Publication number: 20170037049
    Abstract: The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
    Type: Application
    Filed: April 15, 2015
    Publication date: February 9, 2017
    Applicant: PFIZER INC.
    Inventors: DAVID LAWRENCE FIRMAN GRAY, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, SCOT RICHARD MENTE, CHAKRAPANI SUBRAMANYAM
  • Neisseria meningitidis compositions and methods thereof
    Patent number: 9561269
    Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: February 7, 2017
    Assignee: Pfizer Inc.
    Inventors: Gary Warren Zlotnick, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark E. Ruppen, Annaliesa Sybil Anderson, John Erwin Farley, Liesel A. Bernfield
  • Dose unit, pack of dose units and inhaler for inhalation of combination of drugs
    Patent number: 9561336
    Abstract: Various embodiments relate to a dose unit for a dry powder inhaler including: a dose carrier including a plurality of pockets each adapted to contain a dose of medication powder suitable for inhalation, the pockets being sequentially arranged such that the content of the pockets can be sequentially exposed to a flow of air for successive inhalations and a plurality of medication powder doses arranged in the pockets of the dose carrier. The doses are regularly distributed in the pockets according to a sequence of identical groups, each group including at least one blank pocket and one pocket containing a dose of medication powder. Various embodiments also relate to a pack including one such dose unit and one further dose unit with all pockets containing a medication powder. Various embodiments further relate to a dry powder inhaler including such a pack of dose units.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: February 7, 2017
    Assignee: PFIZER LIMITED
    Inventor: Ian Smith
  • 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS
    Publication number: 20170029390
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Application
    Filed: July 28, 2016
    Publication date: February 2, 2017
    Applicant: PFIZER INC.
    Inventors: CHRISTOPHER RYAN BUTLER, LAURA ANN MCALLISTER, ELIZABETH MARY BECK, MICHAEL AARON BRODNEY, ADAM MATTHEW GILBERT, CHRISTOPHER JOHN HELAL, DOUGLAS SCOTT JOHNSON, JUSTIN IAN MONTGOMERY, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, PATRICK ROBERT VERHOEST, DAMIEN WEBB
  • Pyrrolo[2,3-D]pyrimidine derivatives
    Patent number: 9549929
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: January 24, 2017
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
  • Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
    Patent number: 9550795
    Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: January 24, 2017
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Christopher John Helal, Brian Thomas O'Neill
  • ANTI-NOTCH3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20170014526
    Abstract: The present invention provides for anti-Notch3 antibodies, anti-Notch3 antibody-drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: July 27, 2016
    Publication date: January 19, 2017
    Applicant: Pfizer Inc.
    Inventors: Kenneth G. Geles, Yijie Gao, Puja Sapra, Lioudmila Gennadievna Tchistiakova, Bin-Bing Stephen Zhou
  • PYRIMIDINE DERIVATIVES
    Publication number: 20170015689
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1-R11, m, n, and p are defined herein. The novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Application
    Filed: July 13, 2016
    Publication date: January 19, 2017
    Applicant: PFIZER INC.
    Inventors: Ping Chen, Hengmiao CHENG, Gary Michael Gallego, Mehran Jalaie, John Charles Kath, Suvi Tuula Marjukka Orr, Mason Alan PAIRISH
  • Pyrrolo[2,3-D]pyrimidine derivatives
    Patent number: 9545405
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: January 17, 2017
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
  • 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides
    Publication number: 20170008911
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: July 20, 2016
    Publication date: January 12, 2017
    Applicant: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Elizabeth Mary Beck, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Gabriela Barreiro, Erik Alphie LaChapelle, Bruce Nelsen Rogers
  • Substituted 1,7-naphthyridines as dopamine D1 ligands
    Patent number: 9540352
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: January 10, 2017
    Assignee: Pfizer Inc.
    Inventors: David Lawrence Firman Gray, Lei Zhang, Michael Aaron Brodney, Michael Eric Green, Chakrapani Subramanyam
  • NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS
    Publication number: 20170002000
    Abstract: The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Application
    Filed: December 3, 2014
    Publication date: January 5, 2017
    Applicant: Pfizer Inc.
    Inventors: Paul Galatsis, Matthew Merrill Hayward, Bethany Lyn Kormos, Travis T. Wager, Lei Zhang, Jaclyn Louise Henderson, Ravi G. Kurumbail, Patrick Robert Verhoest, Antonia Friederike Stepan
  • SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS
    Publication number: 20160376254
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Applicant: Pfizer Inc.
    Inventors: Michael Raymond COLLINS, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
  • Heteroaromatic compounds and their use as dopamine D1 ligands
    Patent number: 9527843
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: December 27, 2016
    Assignee: PFIZER INC.
    Inventors: Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Chakrapani Subramanyam, Lei Zhang
  • Injector
    Patent number: D776261
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: January 10, 2017
    Assignee: Pfizer Limited
    Inventors: Dawn Jones, David Pearce, Simon Wilson